{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:16:35Z","timestamp":1790388995514,"version":"4.1.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      In Greece, there are high rates of methicillin (40%\u201360%) and clindamycin (15%\u201325%) resistance among community-acquired\n                      <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>\n                      isolates. Therefore, we sought to identify other antimicrobial treatment options such as daptomycin.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We studied retrospectively all pediatric infections treated with daptomycin at the University General Hospital of Larissa, Greece, from January 1, 2007, to June 16, 2016.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Of a total of 128 patients (median age: 2.8 years; range: 8 days to 14.5 years; 76.6% &lt;7 years) treated with daptomycin, 45 (35.2%) had invasive infection, most frequently musculoskeletal, and 83 (64.8%) had noninvasive infection, that is, complicated skin and soft tissue infection.\n                      <jats:italic toggle=\"yes\">S. aureus<\/jats:italic>\n                      was the most commonly recovered pathogen (n = 61) (63.9% methicillin-resistant isolates, 21.3% clindamycin-resistant). The average daily dose of daptomycin was 10\u2009mg\/kg qd, and the median duration of therapy was 10 days. Daptomycin was administered alone (n = 61) or in combination therapy (n = 67), most frequently with rifampin (n = 40) and\/or a \u03b2-lactam antibiotic (n = 33). Open or closed drainage was performed in 86 (67.2%) of the total number of patients. Of 128 treated patients, 123 (96.1%) achieved clinical success, 114 (89.1%) had complete remission, and 9 (7%) had improvement of their disease. There were no failures with daptomycin therapy. The adverse events were of no clinical significance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Daptomycin administered alone or in combination with other antimicrobial agents to children was efficacious and well tolerated in the treatment of complicated infections of suspected or proven staphylococcal etiology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000001629","type":"journal-article","created":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T14:15:19Z","timestamp":1493907319000},"page":"962-966","source":"Crossref","is-referenced-by-count":15,"title":["Daptomycin Use in Children: Experience With Various Types of Infection and Age Groups"],"prefix":"10.1097","volume":"36","author":[{"given":"George A.","family":"Syrogiannopoulos","sequence":"first","affiliation":[{"name":"Department of Microbiology, University of Thessaly, School of Health Sciences, Faculty of Medicine, Larissa, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aspasia N.","family":"Michoula","sequence":"additional","affiliation":[{"name":"Department of Microbiology, University of Thessaly, School of Health Sciences, Faculty of Medicine, Larissa, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efthimia","family":"Petinaki","sequence":"additional","affiliation":[{"name":"Department of Microbiology, University of Thessaly, School of Health Sciences, Faculty of Medicine, Larissa, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna N.","family":"Grivea","sequence":"additional","affiliation":[{"name":"Department of Microbiology, University of Thessaly, School of Health Sciences, Faculty of Medicine, Larissa, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/jama.279.8.593","article-title":"Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk.","volume":"279","author":"Herold","year":"1998","journal-title":"JAMA"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3201\/eid0908.030089","article-title":"Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence.","volume":"9","author":"Vandenesch","year":"2003","journal-title":"Emerg Infect Dis"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.inf.0000073163.37519.ee","article-title":"Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children.","volume":"22","author":"Mart\u00ednez-Aguilar","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/1471-2334-10-351","article-title":"Fusidic acid and clindamycin resistance in community-associated, methicillin-resistant Staphylococcus aureus infections in children of Central Greece.","volume":"10","author":"Katopodis","year":"2010","journal-title":"BMC Infect Dis"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1097\/INF.0b013e31814523f8","article-title":"Daptomycin therapy for invasive Gram-positive bacterial infections in children.","volume":"26","author":"Ardura","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/INF.0000000000000962","article-title":"Use of daptomycin in critically ill children with bloodstream infections and complicated skin and soft-tissue infections.","volume":"35","author":"Tedeschi","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/INF.0000000000001076","article-title":"Clinical experience with daptomycin for the treatment of Gram-positive infections in children and adolescents.","volume":"35","author":"Syriopoulou","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/INF.0000000000001121","article-title":"Daptomycin for children in clinical practice experience.","volume":"35","author":"Garazzino","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1469-0691.2005.01295.x","article-title":"Spread of Staphylococcus aureus clinical isolates carrying Panton-Valentine leukocidin genes during a 3-year period in Greece.","volume":"12","author":"Chini","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1128\/AAC.00247-06","article-title":"Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers.","volume":"50","author":"Benvenuto","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1086\/600039","article-title":"Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program.","volume":"49","author":"Figueroa","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ijantimicag.2010.07.011","article-title":"High-dose daptomycin in documented Staphylococcus aureus infections.","volume":"36","author":"Bassetti","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2415-12-7","article-title":"European ST80 community-associated methicillin-resistant Staphylococcus aureus orbital cellulitis in a neonate.","volume":"12","author":"Tsironi","year":"2012","journal-title":"BMC Ophthalmol"},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/archotol.132.11.1176","article-title":"Increased isolation of methicillin-resistant Staphylococcus aureus in pediatric head and neck abscesses.","volume":"132","author":"Ossowski","year":"2006","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"R17-20230912","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.ijporl.2010.05.030","article-title":"Retropharyngeal and parapharyngeal abscess in children\u2013epidemiology, clinical features and treatment.","volume":"74","author":"Grisaru-Soen","year":"2010","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.ijporl.2012.07.038","article-title":"Antibiotic therapy for pediatric deep neck abscesses: a systematic review.","volume":"76","author":"Carbone","year":"2012","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/lary.23500","article-title":"Changing microbiology of pediatric neck abscesses in Iowa 2000-2010.","volume":"123","author":"Walker","year":"2013","journal-title":"Laryngoscope"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1472-6815-14-8","article-title":"Acute cervical lymphadenitis and infections of the retropharyngeal and parapharyngeal spaces in children.","volume":"14","author":"Georget","year":"2014","journal-title":"BMC Ear Nose Throat Disord"},{"key":"R21-20230912","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/INF.0b013e3181906e40","article-title":"Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate.","volume":"28","author":"Frymoyer","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R22-20230912","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1345\/aph.1P588","article-title":"Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients.","volume":"45","author":"Eiland","year":"2011","journal-title":"Ann Pharmacother"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1097\/INF.0b013e318286378e","article-title":"Improved vancomycin dosing in children using area under the curve exposure.","volume":"32","author":"Le","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R24-20230912","doi-asserted-by":"crossref","first-page":"416","DOI":"10.4212\/cjhp.v67i6.1403","article-title":"Achieving therapeutic vancomycin levels in pediatric patients.","volume":"67","author":"Hoang","year":"2014","journal-title":"Can J Hosp Pharm"},{"key":"R25-20230912","doi-asserted-by":"crossref","first-page":"6192","DOI":"10.1128\/AAC.01525-12","article-title":"\u03b2-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives.","volume":"56","author":"Mehta","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"R26-20230912","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1128\/AAC.02071-15","article-title":"Penicillin binding protein 1 is important in the compensatory response of Staphylococcus aureus to daptomycin-induced membrane damage and is a potential target for \u03b2-lactam-daptomycin synergy.","volume":"60","author":"Berti","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R27-20230912","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s40121-014-0055-5","article-title":"Evaluation of high-dose daptomycin versus vancomycin alone or combined with clarithromycin or rifampin against Staphylococcus aureus and S. epidermidis in a novel in vitro PK\/PD model of bacterial biofilm.","volume":"4","author":"Hall Snyder","year":"2015","journal-title":"Infect Dis Ther"},{"key":"R28-20230912","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/jpids\/piw048","article-title":"Clinical effectiveness, safety profile, and pharmacokinetics of daptomycin in pediatric patients: a systematic review.","volume":"5","author":"Karageorgos","year":"2016","journal-title":"J Pediatric Infect Dis Soc"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201710000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T01:23:31Z","timestamp":1750209811000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201710000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001629","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]}}}